Aurinia Pharmaceuticals Down 3%

Shares of biopharmaceutical company Aurinia Pharmaceuticals Inc. (AUPH) are down 3 percent on Wednesday's trading despite there being no company news to impact the stock.

Aurinia is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the company introduced the first FDA-approved oral therapy indicated for the treatment of adult patients with active lupus nephritis.

Currently at $22.58, the stock has traded between $9.72 and $33.97 during the past 52 weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Follow RTT